There are many reasons to be excited by the science being presented at this year’s American Society for Clinical Oncology meeting. The data...
Via Krishan Maggon
Get Started for FREE
Sign up with Facebook Sign up with X
I don't have a Facebook or a X account
Your new post is loading...
Your new post is loading...
No comment yet.
Sign up to comment
|
Krishan Maggon 's curator insight,
March 9, 2015 6:20 AM
Highlights
• Immune checkpoint blockade inhibitors are revolutionizing the care for patients with cancer. • Specifically, anti-PD-1 and anti-PD-L1 agents have demonstrated marked clinical success in a wide range of malignancies by providing durable benefits with minimal toxicities. • Herein, we review the pre-clinical and clinical activity of these agents in multiple malignancies. • In addition, we review areas that need further development in order to improve the clinical efficacy of these agents.
doi:10.1016/j.molimm.2015.02.009 Molecular Immunology Available online 5 March 2015 In Press, Corrected Proof — Note to users Review Current state of anti-PD-L1 and anti-PD-1 agents in cancer therapy ☆Abhisek Swaika, William A. Hammond, Richard W. Joseph, |